Pharmacy DIR Fees

THE PROBLEM
Retroactive pharmacy DIR fees are the top concern for independent community pharmacists. Part D plan sponsors and pharmacy benefit managers extract direct and indirect remuneration fees from community pharmacies, usually months after a transaction, rather than deducting them from claims on a real-time basis. Those retroactive clawbacks make it extremely difficult for community pharmacists to operate their small businesses when they have no idea whether they'll even break-even on a transaction until months later. Moreover, in January 2017 the Centers for Medicare & Medicaid Services (CMS) warned the rise in pharmacy DIR fees has increased Medicare costs to the government and forced more beneficiaries into the coverage gap, or "donut hole."

THE SOLUTION: Prohibit retroactive DIR fees for pharmacies.
The "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act," S. 413 / H.R. 1038, will prohibit Medicare Part D plan sponsors/PBMs from retroactively reducing payment on clean claims submitted by pharmacies under Medicare Part D.

S. 413 / H.R. 1038 WILL ...

  • Lower Medicare costs for taxpayers. Virtually all catastrophic costs in Part D are borne by the government. These costs, fueled by pharmacy DIR fees, have more than tripled in recent years.1

  • Give seniors reduced cost-sharing and greater budget predictability. Beneficiaries who use their drug plan to fill prescriptions are punished the most by pharmacy DIR fees. This is because retroactive fees lead to inflated drug costs that are the basis for beneficiary cost-sharing amounts.

  • Boost transparency in drug pricing. Prohibiting these pharmacy fees will make the Medicare Plan Finder more accurate and allow better CMS oversight.

  • Preserve access to independent community pharmacies. Locally owned pharmacies provide enhanced patient care, and are often located in underserved rural and inner-city areas. The number of U.S. independent community pharmacies has declined the past five years and a recent study estimated 3 million rural residents are at risk of losing the only pharmacy in their community with the next nearest pharmacy over 10 miles away, a trend exacerbated by DIR. 2

  • Address the concerns of CMS and MedPAC. CMS has noted "variations in the treatment of costs and price concessions affect beneficiary cost sharing, CMS payments to plans, federal reinsurance and low-income cost-sharing (LICS) subsidies, manufacturer coverage gap discount payments, and plan bids." 3 According to MedPAC's 2015 Report to Congress, "MedPAC sees insurers gaming the system to hold premiums down and maximize enrollment."

S. 413 / H.R. 1038 WILL NOT...

  • Lead to unaffordable Medicare Part D premiums. CMS has said that pharmacy DIR fees appear to help restrain premiums. However, there is no evidence to suggest this is a significant factor in premium setting by plan sponsors. Moreover, it is far easier for seniors to budget around monthly premiums than unpredictable cost sharing and any added exposure to the donut hole.

  • Ban "pay-for-performance" programs. S. 413 / H.R. 1038 will allow health plans and PBMs to reward pharmacies for achieving quality-based metrics.

1HHS Office of Inspector General, "High-Price Drugs Are Increasing Federal Payments for Medicare Part D Catastrophic Coverage."

2RUPRI Center for Rural Health Policy Analysis, "Issues Confronting Rural Pharmacies after a Decade of Medicare Part D." April 2017.

3CMS, "Direct and Indirect Remuneration (DIR) and Pharmacy Price Concessions."

TAKE ACTION

Visit our Legislative Action Center to send a letter to your elected officials. Submit a complaint to Medicare using this online complaint form.

Want more information? Check out our PBM Resources page or our Medicare Part D Pharmacy DIR Fees – S. 413 / H.R. 1038 One Pager.